Key clinical point: Approximately one-fifth of patients with hematologic malignancies undergoing hematopoietic stem cell transplantation may develop posttraumatic stress disorder.
Major finding: Six months after transplantation, 18.9% of patients had symptoms of posttraumatic stress disorder.
Study details: An observational study involving 250 adults with hematologic malignancies who underwent hematopoietic stem cell transplantation.
Disclosures: The study was funded by the Lymphoma and Leukemia Society. The investigators disclosed additional relationships with Vector Oncology, Pfizer, AstraZeneca, and Gaido Health/BCG Digital Ventures.
Griffith et al. ASCO 2020. Abstract # 7505.